XM
EPZM

XTX Markets’s Epizyme, Inc EPZM Stock Holding History

XTX Markets’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$124K Buy
+11,434
New +$141K 0.26% 161

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

XTX Markets's EPZM Position: Q4 2020 in Review

XTX Markets opened a new position in Epizyme, Inc (EPZM) in Q4 2020: 11,434 shares worth $124K. The stake represents 0.26% of the portfolio and ranks #161 among its holdings.

137 funds tracked by Wall St. Rank hold EPZM as of Q4 2020.

  • XTX Markets held 11,434 shares of Epizyme, Inc worth $124K as of Q4 2020.
  • Epizyme, Inc was a new XTX Markets position in Q4 2020.
  • Epizyme, Inc made up 0.26% of XTX Markets's portfolio in Q4 2020, its #161 holding.
  • 137 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.